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Background: Both fractionated external beam radiotherapy and single fraction radiosurgery
for pituitary adenomas are associated with the risk of hypothalamic–pituitary (HP) axis
dysfunction.
Objective: To analyze the effect of treatment modality (Linac, TomoTherapy, or gamma
knife) on hypothalamic dose and correlate these with HP-axis deficits after radiotherapy.
Methods: Radiation plans of patients treated post-operatively for pituitary adenomas
using Linac-based 3D-conformal radiotherapy (CRT) (n=11), TomoTherapy-based intensity
modulated radiation therapy (IMRT) (n= 10), or gamma knife stereotactic radiosurgery
(n=12) were retrospectively reviewed. Dose to the hypothalamus was analyzed and
post-radiotherapy hormone function including growth hormone, thyroid stimulating hor-
mone, adrenocorticotropic hormone, prolactin, and gonadotropins (follicle stimulating
hormone/luteinizing hormone) were assessed.
Results: Post-radiation, 13 of 27 (48%) patients eligible for analysis developed at least
one new hormone deficit, of which 8 of 11 (72%) occurred in the Linac group, 4 of 8
(50%) occurred in theTomoTherapy group, and 1 of 8 (12.5%) occurred in the gamma knife
group. Compared with fractionated techniques, gamma knife showed improved hypothala-
mic sparing for DMax Hypo and V12Gy. For fractionated modalities, TomoTherapy showed
improved dosimetric characteristics over Linac-based treatment with hypothalamic DMean
(44.8 vs. 26.8 Gy p=0.02), DMax (49.8 vs. 39.1 Gy p=0.04), and V12Gy (100 vs. 76%
p=0.004).
Conclusion: Maximal dosimetric avoidance of the hypothalamus was achieved using
gamma knife-based radiosurgery followed by TomoTherapy-based IMRT, and Linac-based
3D conformal radiation therapy, respectively.
Keywords: pituitary adenoma, tomotherapy, gamma knife, hypothalamus, endocrinopathy, IMRT, 3D conformal
radiotherapy
INTRODUCTION
Radiotherapy plays an integral role in the management of patients
with pituitary adenomas, and this includes both fractionated
external beam radiotherapy (EBRT) and stereotactic radiosurgery
(SRS). Fractionated EBRT and SRS both afford excellent local
control rates for pituitary adenomas, generally on the order of
90% at 10 years (1–3). Both fractionated EBRT and SRS put
patients at risk for functional endocrine deficits, which is both
a dose and time dependent phenomenon (4). Such abnormali-
ties include deficits in growth hormone (GH), prolactin (PRL),
adrenocorticotropic hormone (ACTH), thyroid stimulating hor-
mone (TSH), and gonadotropins follicle stimulating hormone
(FSH) and luteinizing hormone (LH), with GH generally being
the most radiosensitive endocrine axis (5). In comparison to
fractionated EBRT, SRS affords a more convenient option for
patients and is becoming a more frequently used modality of
treatment (6). However, certain tumor and patient selection
criteria may require the use of fractionated radiotherapy. For
instance, at the Medical College of Wisconsin (MCW), the use
of SRS is generally reserved for patients with pituitary tumors
<3 cm in size and with at least 3 mm clearance from the optic
chiasm (OC).
The hypothalamus plays a critical role in the functioning
of the hypothalamic–pituitary (HP) axis, and radiation-induced
injury is believed to affect both the pituitary and the hypo-
thalamus (7). Doses to the hypothalamus as low as 12 Gy may
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be implicated in increasing the risk of radiotherapy associated
endocrinopathies, and doses typically used in the treatment
of brain tumors (>50 Gy) commonly result in HP-axis defi-
ciency (8, 9). To better understand the relationship between
hypothalamic dose and endocrine dysfunction, we reviewed
patients undergoing treatment for pituitary adenomas at our
institution. Hypothalamic dose characteristics were analyzed
by treatment modality [Linac-based 3D-conformal radiotherapy
(CRT), TomoTherapy-based intensity modulated radiation ther-
apy (IMRT), and gamma knife SRS], and endocrine outcomes were
assessed accordingly.
MATERIALS AND METHODS
PATIENTS
Between December 2005 and January 2012, 33 patients were iden-
tified with pituitary adenomas who underwent gamma knife SRS
(n= 12), fractionated TomoTherapy-based IMRT (n= 10), or
fractionated Linac-based 3D-CRT (n= 11). All aspects of this ret-
rospective study were approved by the MCW Institutional Review
Board. All patients analyzed had routine endocrine follow-up
at MCW, and clinical data were obtained from the institutional
electronic medical record. Dosimetric information was acquired
through restoration of the original treatment plans maintained
in the departmental database. Baseline patient characteristics are
described in Table 1. Pre-radiotherapy endocrine deficits were
present in 84.8% of patients, and 45% of patients had function-
ing adenomas vs. 55% non-functioning. Of all adenomas, 30%
were GH secreting, 12% PRL secreting, and 3% ACTH secret-
ing. Four patients were treated with medical therapy to oppose
hypersecretory function prior to surgery (two patients treated
with a dopamine agonist for PRL secretion in the TomoTherapy
group, and two patients treated with octreotide for GH secre-
tion in the gamma knife group). All patients had previously
undergone endonasal transsphenoidal surgery. All patients were
diagnosed with macroadenomas and underwent a subtotal resec-
tion except one patient in the Linac group who underwent a biopsy
only. The median study follow-up period was 24 months (range
2–76 months).
Table 1 | Baseline patient characteristics.
Linac Tomo
Therapy
Gamma
knife
Total
N 11 10 12 33
Male (%) 6 (54.5) 6 (60) 5 (41.5) 17 (51.5)
Female (%) 5 (45.5) 4 (40) 7 (58.3) 16 (48.5)
Mean age 43.8 49.2 46 44.4
Transsphenoidal resection (%) 100 100 100 100
Deficit prior to RT (%) 6 (54.5) 10 (100) 12 (100) 28 (84.8)
Non-functioning adenoma (%) 5 (45) 6 (60) 7 (58) 18 (55)
Functioning adenoma (%) 6 (55) 4 (40) 5 (42) 15 (45)
GH secreting (%) 5 (45) 1 (10) 4 (33) 10 (30)
PRL secreting (%) 0 (0) 3 (30) 1 (8) 4 (12)
TSH secreting (%) 0 (0) 0 (0) 0 (0) 0 (0)
ACTH secreting (%) 1 (9) 0 (0) 0 (0) 1 (3)
RADIOTHERAPY
Linac-based 3D-CRT was performed on one of three institutional
linear accelerators. Plans were based on a five field non-coplanar
design including an anterior “vertex” field requiring a 90° couch
rotation. Radiation dose to the target volume ranged from 48.6 to
54 Gy. All 3D-CRT planning was performed using Xio radiation
treatment planning software (Elekta/CMS, St Louis, MO, USA).
TomoTherapy-based IMRT was performed on the institutional
TomoTherapy unit. IMRT planning was performed using the
TomoTherapy radiation planning system (TomoTherapy, Madi-
son, WI, USA). Radiation dose to the target volume ranged from
50 to 54 Gy.
Gamma knife SRS was performed using the Leksell Gamma
knife (Elekta AB, Stockholm, Sweden). MRI imaging with a stereo-
tactic head frame was acquired for treatment planning for each
case, and planning was performed using Leksell GammaPlan soft-
ware (Elekta AB, Stockholm, Sweden). Radiation dose to the target
volume ranged from 12 to 20 Gy in a single fraction prescribed to
the 50% isodose line (IDL).
In this study group at the time of treatment planning and deliv-
ery, the hypothalamus was not explicitly contoured, monitored, or
identified as an avoidance structure for any of the three treatment
techniques.
The determination of eligibility for SRS vs. fractionated EBRT
was made primarily based on size of the tumor and distance
from the OC, with a requirement of <3 cm tumor with >3 mm
clearance from the OC preferred for SRS. The use of 3D-CRT
vs. TomoTherapy IMRT was practitioner dependent and partially
determined by the year of treatment and the availability of the
modality, with a trend toward increased use of TomoTherapy dur-
ing the later years of the study period. Linac-based IMRT was
not performed due to the perceived improved conformality of
TomoTherapy over Linac-based IMRT during the study period.
DOSIMETRIC ANALYSIS
In order to analyze hypothalamic dose characteristics of each treat-
ment plan, a hypothalamic contour was retrospectively added in
each case. For patients treated with Linac-based 3D-CRT, the treat-
ment plan was restored into the Xio radiation planning system and
the hypothalamic contour was added to the structure set, such that
dose–volume histogram (DVH) data for the hypothalamus could
be acquired. For patients treated with TomoTherapy, plans were
restored into both Xio (to allow the hypothalamic contour to be
added) and the TomoTherapy planning system (to recover the dose
data itself) and fused into Focal (Elekta AB, Stockholm, Sweden)
such that dose data from the original plan could be applied to
the new hypothalamic contour. For patients treated with gamma
knife SRS, the hypothalamic contour was added in Leksell Gamma
Plan such that DVH data could be analyzed. Contouring within
Gamma Plan was performed directly onto the pre-treatment MRI
data set originally acquired using the MRI T1 sequence with con-
trast. Contouring was performed on pre-radiotherapy MRI T1
weighted images.
After restoration of all plans and construction of the hypo-
thalamic contour was complete, the following parameters were
determined: target volume, prescription dose, volume of the hypo-
thalamus, volume of the hypothalamus receiving at least 12 Gy
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(V12Gy), Mean hypothalamic dose (DMean Hypo), Maximum
hypothalamic dose (DMax Hypo), and the Biologically Equivalent
Dose at 2 Gy/Fx for α/β= 3 (BED2Gy).
HYPOTHALAMIC CONTOURING
The hypothalamic contour was created using MRI-based anatomic
landmarks representing surrogate boundaries for the hypothala-
mus itself. Contouring was performed with the assistance of an
MCW neuroradiologist, and contours were reviewed by the senior
author (Joseph A. Bovi). Previously published MRI Atlases of the
hypothalamus were referenced to identify anatomic landmarks as
boundaries for the hypothalamic contour (10, 11). The contour-
ing procedure was also in accordance with a previously published
hypothalamic contouring method (8). The hypothalamic contour
was a polygonal structure consisting of two separated volumes on
each side of the third ventricle or CSF space. The superior most
boundary of the contour was set at the axial slice containing the
anterior commissure (AC). The inferior most boundary was set at
the axial slice containing the OC. Anteriorly, the boundary con-
sisted of the anterior aspect of the third ventricle or the visible
edge of the CSF space within the suprasellar cistern. Posteriorly,
the contour was drawn to the level of the interpeduncular fossa.
The medial border consisted of the third ventricle or the visi-
ble CSF space. Laterally, the contour was bounded by the optic
white matter tracts or the internal capsule. Representative slices
are depicted in Figure 1.
ENDOCRINE EVALUATION
Baseline endocrine evaluation was performed on all analyzed
patients under the direction of MCW neuroendocrinologists. Each
patient had baseline pre-radiotherapy endocrine labs drawn, as
well as post-radiotherapy follow-up labs at 6–12 month intervals
after treatment indefinitely. Standard endocrine laboratory stud-
ies included evaluation of PRL, GH which was evaluated through
IGF-1, thyroid studies (TSH and free T4), ACTH which was
evaluated with eight AM fasting cortisol, ACTH, and eight AM
fasting cosyntropin stimulation test, and gonadotropin function
evaluated with estradiol or testosterone, LH and FSH or normal
menstrual status in premenopausal women. Reference ranges were
as follows: PRL (2.8–23.3 ng/mL female, 4.0–15.2 ng/mL male),
IGF-1 (reference range varies with age), TSH (0.45–4.5µIU/mL),
free T4 (0.82–1.77 ng/dL), eight AM cortisol (>10µg/dL), ACTH
(7.2–63.3 pg/mL), FSH (male, 1.5–12.4 mIU/mL, female post
menopause 25.8–134.8 mIU/mL, female pre-menopause with
normal menstrual cycles considered normal, reference ranges
are phase dependent), LH (male, 1.7–8.6 mIU/mL, female post
menopause 7.7–58.5 mIU/mL, female pre-menopause with nor-
mal menstrual cycles considered normal, reference ranges are
phase dependent). Laboratory reference ranges varied slightly
during the study period; however, all laboratory values were ref-
erenced to the normal ranges listed at the time of lab draw.
Pre-radiotherapy deficit was defined as any laboratory values
below the reference ranges or any administration of hormone
FIGURE 1 | Representative slices of MRIT1+C images registered to
CT data sets for hypothalamic volume contouring. Slices A (superior
most) through F (inferior most) depict several anatomic landmarks for the
delineation of the hypothalamic contour (red). (A) Depicts the superior
most slice, at the level of the anterior commissure. (B–E) Depict the
hypothalamic contour, bounded by the white matter tracts laterally, the
third ventricle medially, the CSF space of the suprasellar cistern
anteriorly, and the level of the interpeduncular fossa posteriorly.
(F) Depicts the level of the optic chiasm, at which the contour ends.
The contour has been enhanced for ease of visibility.
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replacement therapy prior to the start of radiotherapy. Post-
radiotherapy endocrinopathy in any axis (PRL, GH, ACTH, TSH,
or FSH/LH) was defined as laboratory values on at least two sepa-
rate lab draws below the reference range identified on a follow-up
evaluation, or administration of hormone replacement therapy
(such as levothyroxine, hydrocortisone/prednisone, human GH,
estrogen/progesterone, or testosterone) as judged necessary by the
treating neuroendocrinologist. In addition, PRL elevation post-
radiotherapy in a previously non-PRL secreting adenoma was
categorized as an endocrine abnormality. Any endocrine labora-
tory value outside the reference range on a single assessment that
subsequently normalized without the administration of hormone
therapy was not considered to constitute an endocrinopathy.
STATISTICAL ANALYSIS
With respect to endocrine evaluation, new HP-axis deficits that
were not present prior to radiotherapy were considered the pri-
mary endpoint. HP-axis event curves using the Kaplan–Meier
method were performed, with a new endocrinopathy in any of
the five endocrine axes (GH, PRL, ACTH, TSH, or Gonadotropin)
constituting an event in the analysis. If multiple endocrinopathies
occurred within the same patient, the first endocrinopathy was
used for the event curve analysis. Univariate analysis of event free
survival by treatment modality was performed using the log-rank
test. With respect to dosimetric evaluation, parameters analyzed
included hypothalamic mean dose (DMean Hypo), hypothalamic
maximum dose (DMax Hypo), and the percentage of hypothala-
mic volume receiving ≥12 Gy (V12Gy). Dosimetric comparisons
by treatment modality for all three groups were performed using
one-way ANOVA. TomoTherapy comparison with Linac-based
therapy was performed using the Exact Wilcoxon Rank Sum test.
Statistics were performed in consultation with the MCW depart-
ment of Biostatistics using SAS statistics software version 9.3 (The
SAS Institute, Cary, NC, USA) and significance was determined by
a p< 0.05.
RESULTS
DOSIMETRIC COMPARISONS
Dosimetric data are presented in Table 2. With respect to the
fractionated techniques there was no difference between the Linac-
treated group and the TomoTherapy group in terms of target
volume (12.7 and 24.5 cc, respectively), prescription dose (50.4
and 50.68 Gy, respectively), volume of the hypothalamus (0.81
and 0.93 cc, respectively), and BED 2 Gy (48.4 and 49.1 Gy, respec-
tively). When comparing the fractionated techniques, there was
an improvement in the TomoTherapy group over the Linac group
with respect to the hypothalamic V12Gy (76 vs. 100% p= 0.004),
DMean (44.8 vs. 26.8 Gy p= 0.02), and DMax (49.8 vs. 39.1
p= 0.04). The gamma knife group was superior to both frac-
tionated techniques in terms of DMax (1.6 Gy) and V12Gy (0%),
however DMean for the gamma knife group was not calculated.
The hypothalamic volume of the gamma knife group was smaller
than that of either of the fractionated groups, likely reflecting dif-
ferences in the contouring mechanism and the slice thickness of
the MRI images available for the Gamma Plan system.
All gamma knife parameters were significantly different than
the respective fractionated radiotherapy parameters by the exact
Kruskal–Wallis Test. p Values reflect comparison of Linac vs.
Tomotherapy by the exact Wilcoxon Rank Sum Test.
PATIENT SURVIVAL, LOCAL CONTROL, AND ENDOCRINE OUTCOMES
All patients were alive and disease free during the study period
after completion of fractionated EBRT or gamma knife radio-
surgery. No patient exhibited local recurrence as assessed by MRI
imaging during follow-up.
Prior to radiotherapy, 28 of 33 (84.8%) of patients had at
least one baseline endocrine deficit. Post-radiotherapy for all
groups, new endocrine deficits occurred in 13 of 27 (48%) of
patients eligible for analysis. A total of 20 new endocrine deficits
were identified, with some patients developing more than one
endocrinopathy. Deficits by treatment modality were as follows:
in the Linac-based 3D-CRT treated group 8 of 11 (72%) patients
developed at least one new endocrinopathy, whereas this occurred
in 4 of 8 (50%) patients treated with TomoTherapy IMRT and
1 of 8 (12.5%) patients treated with gamma knife SRS. Specific
endocrine deficits by treatment modality are displayed in Table 3.
Of 20 new endocrine deficits identified, 5 (25%) each involved GH,
TSH, and PRL, 2 (10%) involved ACTH, and 3 (15%) involved
LSH/FSH.
The median event free duration of the functioning pre-
radiotherapy hypothalamic–pituitary axes were 18.7 months in the
Linac 3D-CRT treatment group, 48.9 months in the TomoTher-
apy IMRT treatment group, and was not reached in the gamma
knife SRS treatment group. The pre-radiotherapy intact endocrine
axis event curves for each group are displayed in Figure 2. Event
Table 2 | Dosimetric parameters by treatment modality.
Parameter Linac Tomo
Therapy
Gamma
knife
p
Target volume (cc) 12.7 24.5 3.0 0.7
Hypothalamic volume (cc) 0.8 0.9 0.5 0.28
V12Gy Hypo 100% 76% 0% 0.004
DMean Hypo 44.8 Gy 26.8 Gy NA 0.02
DMax Hypo 49.8 Gy 39.1 Gy 1.6 Gy 0.04
BED2 α/β 3 48.4 Gy 49.1 Gy 60.6 Gy 0.64
Mean prescription dose 50.4 Gy 50.7 Gy 15.8 Gy 0.66
BED2 α/β 3, biologically equivalent dose at 2Gy per fraction for an α/β ratio of 3.
Table 3 | Specific endocrine deficits by treatment modality.
Hormone
abnormality
Linac Tomo
Therapy
Gamma
knife
Total (%)
GH 4 1 0 5 (25)
PRL (↓) 1 0 0 1 (5)
PRL (↑) 2 1 1 4 (20)
ACTH 2 0 0 2 (10)
TSH 3 2 0 5 (25)
LSH/FSH 3 0 0 3 (15)
Total 15 4 1 20 (100)
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FIGURE 2 | Kaplan–Meier event curves of pre-radiotherapy intact
hypothalamic–pituitary axes as a function of time post-radiotherapy.
Occurrence of any new endocrinopathy constitutes an event in the plot.
Event curve hazard ratios do not differ statistically by the log-rank test.
curve separation was not statistically significant by the log-rank
test (p= 0.36).
DISCUSSION
One of the most common complications of treatment for pitu-
itary adenomas is endocrine dysfunction, and for this reason long
term follow-up is critical to optimize patient outcomes. This risk
as it relates to radiotherapy is a phenomenon that depends on
dose to the HP-axis, the volume of irradiated tissue, the time
interval after irradiation, and underlying HP-axis pathology (12).
Patients undergoing both fractionated EBRT and SRS are sub-
ject to this risk. Typically endocrinopathies manifest within the
first 3 years of treatment, however they can also occur much later
(13). Despite the consistent finding that irradiation of pituitary
tumors places the patient at risk for hypopituitarism, reports of
the actual incidence of treatment-associated endocrine deficits
vary widely among both fractionated and radiosurgical series (14,
15). The reason for this heterogeneity is likely multifactorial and
involves numerous issues such as the type and extent of surgery
prior to radiotherapy, the pre-treatment effect of the tumor itself
on the HP-axis, the type of radiotherapy technique, the follow-
up interval, and the definition of endocrine dysfunction used.
Various definitions of post-treatment endocrine dysfunction have
been employed such as the use of strict laboratory cutoff val-
ues vs. the administration of hormone replacement therapy, or a
combination thereof (16–19).
In this study, the definition of new endocrine deficit included
both a consistently abnormal laboratory value as well as the
administration of hormone replacement therapy in order to cap-
ture these two issues. By doing so, however this study may reflect
relatively higher rates of endocrinopathy in comparison to other
series. Additionally, it is uncommon to report post-radiotherapy
PRL elevation as a new HP-axis endocrinopathy, as this is unlikely
to cause symptoms or require intervention. However, this particu-
lar abnormality does give insight into the mechanism of dysfunc-
tion,as the hypothalamus is known to exert a tonic inhibitory effect
on the secretion of PRL by the anterior pituitary through the neu-
rotransmitter dopamine (20, 21). Presumably, a post-radiotherapy
rise in PRL would represent damage sustained by the hypothala-
mus reflected by the inability to maintain this tonic inhibition,
and in certain circumstances can be opposed through the use of a
dopamine agonist (22).
The exact contribution of the hypothalamus to post-
radiotherapy anterior pituitary endocrine deficits is not entirely
elucidated, however it is postulated that endocrine changes result-
ing from hypothalamic damage may occur within a shorter time
frame than those associated with damage to the pituitary itself.
Agha et al. analyzed HP-axis deficiencies in adults treated with
radiotherapy for non-pituitary brain tumors and found that mild
to moderate hyperprolactinemia occurred at a shorter median
time (33 months) in comparison to GH, ACTH, or gonadotropin
deficiency (100 months), possibly reflecting an earlier manifes-
tation of hypothalamic dysfunction in comparison to pituitary
dysfunction (18).
Studies of GH deficiency in pediatric patients treated for pri-
mary brain tumors as well as total body irradiation (TBI) have
revealed that the hypothalamus plays an important role in the
pathogenesis of this disorder. Merchant et al. investigated the
relationship of the dose to the hypothalamus in the develop-
ment of GH deficiency and determined that a dose of 16.1 Gy
to the hypothalamus would constitute the mean dose required to
induce a 50% risk of GH deficiency at 5 years post-radiotherapy
(23). GH is known to be the most susceptible endocrine axis to
radiotherapy-induced dysfunction, and hypothalamic doses as low
as 12 Gy may result in impaired GH release (8). Although suscepti-
bility of the hypothalamus to radiation-induced dysfunction may
be more pronounced in children, the same phenomenon has been
noted in adult patients as well. Feigl et al. investigated the hypothal-
amic dose received by 108 patients treated with gamma knife SRS
for pituitary adenomas and found that the mean dose was higher
in patients with new endocrinopathies than in those without (1.3
vs. 0.8 Gy) (17).
Overall endocrine dysfunction likely reflects the combined
effect of damage to both structures (5, 7, 14). In clinical practice,
however it is not useful or cost effective to routinely differentiate
secondary endocrine deficiencies from tertiary endocrine deficien-
cies (i.e., anterior pituitary vs. hypothalamic) as this distinction
would not typically alter management.
Given the role played by the hypothalamus in the develop-
ment of radiation-induced hypopituitarism, dose monitoring to
this structure with the aim of maximal avoidance is a rational
objective. In this study, the parameters DMax Hypo and DMean
Hypo were chosen as dose monitoring parameters analogous to
those commonly employed for other treatment planning organs
at risk (OAR). The parameter V12 Hypo (the volume of the
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hypothalamus receiving 12 Gy) was chosen as possibly reflective of
a “threshold dose” in the fractionated setting, as it has previously
been shown through TBI data that dysfunction of the most sensi-
tive HP-axis, GH, is rare with exposure of<12 Gy (9). In addition,
in the radiosurgical setting, the volume of brain receiving>12 Gy
has been described in QUANTEC as a marker for increased normal
tissue complication risk (24).
In this study, dose sparing to the hypothalamus was consid-
erably more favorable in the gamma knife SRS group over the
fractionated techniques. This was an expected result, given the
highly conformal nature of the gamma knife system and steep
dose gradients associated with this technique. It is important to
note that to be eligible for this procedure patients must meet cer-
tain requirements in terms of tumor size and distance from the
optic structures.
With respect to the fractionated techniques, helical
TomoTherapy-based IMRT exhibited improved hypothalamic
dose sparing in comparison to Linac-based 3D-CRT, likely in part
due to the characteristic anterior vertex field of the 3D plans,
which projects through the hypothalamus. Improved conformality
through IMRT inverse planning is not unique to TomoTherapy, as
Linac-based IMRT techniques are capable of producing improved
dosimetric profiles in comparison to the Linac-based 3D tech-
nique; however this issue was not addressed during the study
period as most treating physicians were more comfortable with
the use of TomoTherapy IMRT in this setting. The endocrine
outcomes of the patients in each of these three groups trended
toward improved HP-axis preservation paralleling the hypothal-
amic sparing properties of the techniques used, however larger
patient sample and longer follow-up would likely be required to
further clarify the association. Furthermore, routinely incorporat-
ing the hypothalamic contour may allow for improved conformal
avoidance with either fractionated 3D-CRT or IMRT techniques.
CONCLUSION
In patients treated post-operatively for pituitary adenomas, hypo-
thalamic dose sparing was best achieved using gamma knife-
based radiosurgery. With respect to fractionated radiotherapy,
TomoTherapy IMRT provides improved hypothalamic dose spar-
ing over Linac-based 3D-CRT. Efforts to minimize hypothal-
amic dose by monitoring parameters such as DMax Hypo,
DMean Hypo, and V12Gy may improve endocrine outcomes
post-radiotherapy.
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